Study data

(8537583), Walter R. J. Taylor; (10905688), Niamh Meagher; (148722), Benedikt Ley; (148725), Kamala Thriemer; (34875), Germana Bancone; (16943021), Ari Satyagraha; (776696), Ashenafi Assefa; (16939310), Krisin Chand; (13744510), Nguyen Hoang Chau; (351592), Mehul Dhorda; (16943024), Tamiru S. Degaga; (14241842), Lenny L. Ekawati; (59005), Asrat Hailu; (16939316), Mohammad Anwar Hasanzai; (16939313), Mohammad Nader Naddim; (8842943), Ayodhia Pitaloka Pasaribu; (13744507), Awab Ghulam Rahim; (391795), Inge Sutanto; (16943027), Ngo Viet Thanh; (16943030), Nguyen Thi Tuyet-Trinh; (8188137), Naomi Waithira; (802684), Adugna Woyessa; (229103), Arjen Dondorp; (45473), Lorenz von Seidlein; (242873), Julie A. Simpson; (35779), Nicholas J. White; (7464932), J. Kevin Baird; (12366670), Nicholas P. Day; (7464974), Ric N. Price

doi:10.1371/journal.pntd.0011522.s008

Public

Study data.

Published in Figshare • Sep 6, 2023

NobleIDNI9P83W95R51S88

Authors:

Walter R. J. Taylor (8537583)

,

Niamh Meagher (10905688)

,

Benedikt Ley (148722)

Abstract

<div>BackgroundThe World Health Organization recommends that primaquine should be given once weekly for 8-weeks to patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase (G6PD) deficiency, but data on its antirelapse efficacy and safety are limited.Metho...

Subject

Medicine

Primaquine

Malaria

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!